Pliant Therapeutics Inc PLRX
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-06-03 |
| Shares Out. | 61,920,000 |
| Website | pliantrx.com/ ↗ |
| Phone | 16504816770 |
| Employees | 49 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$22.4M |
| Free Cash Flow | -$70.9M |
| Total Assets | $189.9M |
| Total Liabilities | $43.0M |
| Equity | $146.9M |
About Pliant Therapeutics Inc
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Pliant Therapeutics Inc is a publicly traded company under the ticker symbol PLRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-09-01)